|
| |
Image Results
Loading...
Loading...
Prosidion Ltd Pages on BioPortfolio:
|
BioPortfolio - Prosidion Ltd patents
Prosidion Ltd patents - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/28722-Prosidion+Ltd...
|
BioEmail – Email lists for specifically targeting professionals ...
Prosidion Ltd, Watlington Road, Oxford. • Prolysis Ltd., Begbroke Science Park, Sandy Lane, Yarnton Oxfordshire. • Oxford Biosensors Limited, Oxford ...
http://www.bioportfolio.com/pdf/fermentors.pdf...
|
BioPortfolio News: Dvc - DVC Deutsche Venture Capital achieves a...
DVC Deutsche Venture Capital achieves a substantial return on the asset sale of portfolio company Probiodrug to Prosidion Ltd. ...
http://www.bioportfolio.com/news/DVC_Deutsche_Venture_Capita...
|
BioPortfolio - Dvc - Life Sciences Day of DVC Deutsche Venture ...
1 Jul 2004 ... UK biotech company Prosidion Ltd. Interesting insights into the biotech area in Germany and Europe from the perspective of academia, ...
http://www.bioportfolio.com/news/Life_Sciences_Day_of_DVC_De...
|
BioPortfolio - Glycogen Phosphorylase
Prosidion Ltd. (OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and ...
http://www.bioportfolio.com/indepth/Glycogen_Phosphorylase.h...
|
BioPortfolio - Most Popular Pages on Biocorporate
Upstate Biotechnology Incorporated, 23859, 5665. Murex Biotech Limited, 7647, 1594. Transduction Laboratories, 6594, 1455. Prosidion Ltd, 6080, 1440 ...
http://www.bioportfolio.com/biocorporate/mostlinkedout.php...
|
BioPortfolio News: Dvc - Life Sciences Day of DVC Deutsche...
... announced a planned IPO on the Frankfurt Stock Exchange and Probiodrug elaborated on the $ 35 million deal with the UK biotech company Prosidion Ltd.
...
http://www.bioportfolio.com/news/Life_Sciences_Day_of_DVC_De...
| Results from other life science and pharmaceutical sites:
Shaping Medicine, Changing Lives
OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, ...
http://www.osip.com/...
|
Modulation of extracellular matrix genes reflects the magnitude of ...
6OSI Prosidion Ltd, Oxfordshire, OX4 6LT, UK. Corresponding author. James A Timmons: Jamie.Timmons/at/cgb.ki.se; Eva Jansson: Eva.Jansson/at/labtech.ki.se;
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1224855/...
|
BMC Biology
Enabling Technologies, AstraZeneca, Alderly Park, UK and 6OSI Prosidion Ltd, Oxfordshire, OX4 6LT, UK. Email: James A Timmons* - Jamie.Timmons@cgb.ki.se; ...
http://www.biomedcentral.com/content/pdf/1741-7007-3-19.pdf...
|
Applying science to drug discovery.
Prosidion Ltd, Watlington Road, Oxford OX4 6LT, UK. jmccormack@prosidion.com. Scientists and science in the pharmaceutical industry rely heavily on the more
...
http://www.ncbi.nlm.nih.gov/pubmed/16545084...
|
1741-7007-3-19 1741-7007 Research article Modulation of ...
Ridden@AstraZeneca.com Rachman Jonathan jrachman@prosidion.com Sundberg Johan ... AstraZeneca, Alderly Park, UK OSI Prosidion Ltd, Oxfordshire, OX4 6LT, ...
http://www.biomedcentral.com/content/download/xml/1741-7007-...
|
Anker Lundemose, M.D., Ph. D.
He was appointed Executive VP, OSI Pharmaceuticals, Inc. and President, (OSI) Prosidion, in March 2005 having been the CEO of Prosidion Limited since the ...
http://www.osip.com/mgmt_lundemose...
|
BioMed Central | Abstract | Modulation of extracellular matrix ...
2 Sep 2005 ... 6OSI Prosidion Ltd, Oxfordshire, OX4 6LT, UK. author email corresponding author email. BMC Biology 2005, 3:19doi:10.1186/1741-7007-3-19 ...
http://www.biomedcentral.com/1741-7007/3/19/abstract...
|
OSI Pharmaceuticals, Inc. - Google Finance
OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom ...
http://www.google.com/finance?q=NASDAQ:OSIP...
|
NovImmune - Turning Science into Medicine - Management Team
... to OSI Pharmaceuticals Inc./Prosidion ltd. Arnd has more than 13 years of international experience in finance and operations and merger and acquisition.
...
http://www.novimmune.com/about-us/management-team.html...
|
PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 ...
We thank the following for their contributions to this work: J Bloxham, JG Mc Cormack, M Procter and PS Widdowson (Prosidion Limited). ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=21...
|
|
